Consequently, inhibition of MALT1 proteolytic activity has been proposed as an interesting therapeutic approach for autoimmune diseases and certain cancers, which is further supported by promising results with MALT1 protease inhibitors in preclinical mouse models (12, 13, 35–37). Here, MALT1 is linked to autoimmune disease.